Augmedix (NASDAQ:AUGX) Third Quarter 2023 Results
Key Financial Results
-
Revenue: US$11.8m (up 50% from 3Q 2022).
-
Net loss: US$4.41m (loss narrowed by 20% from 3Q 2022).
-
US$0.097 loss per share (improved from US$0.15 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Augmedix Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
Performance of the American Healthcare Services industry.
The company's shares are up 9.0% from a week ago.
Risk Analysis
It is worth noting though that we have found 3 warning signs for Augmedix that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.